23 recruiting, 12 not yet recruiting, 8 active not recruiting, 1 completed. 17 Phase 3, 16 Phase 2, 4 Phase 1, 3 Not applicable.
Follow Nasopharyngeal Cancinoma (NPC): new trials by email Literature Review of Nasopharyngeal Cancinoma (NPC) trials Research Report on Nasopharyngeal Cancinoma (NPC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| Platinum-Free Regimen in Nasopharyngeal Carcinoma Endostar (recombinant human endostatin injection) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 145 | 2026-09-01 | 2026-08-31 |
| Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma Multimodal Evaluation-Guided Surveillance Strategy - Nasopharyngeal Cancinoma (NPC) | Not applicable | Not yet recruiting | Xuelei Ma MD | 80 | 2026-08-01 | 2026-07-09 |
| Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Maintenance Immunotherapy With Deferred Salvage Radiotherapy - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Recruiting | Sun Yat-sen University | 62 | 2026-07-22 | 2026-07-23 |
| Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma Anti-PD1, Anti-PD1 combined with Becotatug Vedotin - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 86 | 2026-07-20 | 2026-07-15 |
| Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Gemcitabine + cisplatin (GP) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 514 | 2026-04-01 | 2026-04-13 |
| Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab - Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC) | Phase 1 | Recruiting | West China Hospital | 9 | 2026-03-27 | 2026-09-02 |
| Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma GP plus Toripalimab Induction chemotherapy+CCRT, TP plus Toripalimab Induction chemotherapy+CCRT, TPC plus Toripalimab Induction chemotherapy+CCRT - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Recruiting | Sun Yat-sen University | 243 | 2026-03-12 | 2026-03-17 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy Becotatug vedotin - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Recruiting | Sun Yat-sen University | 59 | 2026-02-10 | 2026-04-13 |
| MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial Becotatug Vedotin and Pucotenlimab - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | West China Hospital | 30 | 2026-02-01 | 2026-02-13 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 418 | 2026-01-15 | 2026-01-28 |
| LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC Gemcitabine(GEM), Cisplatin, Toripalimab - Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2026-01-12 | 2026-05-22 |
| IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features IMRT along - Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy | Recruiting | Qiaojuan Guo | 169 | 2026-01-12 | 2026-01-29 | |
| International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer Nasopharyngeal Cancinoma (NPC) | Recruiting | The University of Hong Kong-Shenzhen Hospital | 5000 | 2026-01-09 | 2026-05-04 | |
| Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis - Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis | Phase 3 | Recruiting | Sun Yat-sen University | 386 | 2025-12-16 | 2026-05-07 |
| Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 516 | 2025-12-01 | 2025-11-20 |
| Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy Proton chemoradiotherapy, Photon chemoradiotherapy - NPC Patients, Nasopharyngeal Cancinoma (NPC) | Recruiting | Cheng-En Hsieh | 500 | 2025-11-20 | 2025-11-24 | |
| Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. Radiation Therapy - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Active not recruiting | Sun Yat-sen University | 700 | 2025-11-17 | 2026-08-27 |
| Adaptive Immunotherapy for Nasopharyngeal Carcinoma Radical radiotherapy of nasopharynx and neck, Capecitabine, Concurrent chemoradiotherapy (cCRT) - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 802 | 2025-11-13 | 2025-11-25 |
Showing 20 of 44. Sign in to see all of them.
Nasopharyngeal Carcinoma (15) · Nasopharyngeal Neoplasms (7) · Anorexia (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Epstein-Barr Virus Infections (1) · Head and Neck Neoplasms (1) · Lymphatic Metastasis (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tertiary Lymphoid Structures (1) · Weight Loss (1)
Neoplasms (22) · Neoplasms by Site (22) · Head and Neck Neoplasms (21) · Nasopharyngeal Diseases (21) · Otorhinolaryngologic Diseases (21) · Otorhinolaryngologic Neoplasms (21) · Pharyngeal Diseases (21) · Pharyngeal Neoplasms (21) · Stomatognathic Diseases (21) · Carcinoma (16) · Neoplasms by Histologic Type (16) · Neoplasms, Glandular and Epithelial (16) · Nasopharyngeal Neoplasms (14) · Pathological Conditions, Signs and Symptoms (3) · Body Weight (1)
Cisplatin (12) · Gemcitabine (9) · Capecitabine (5) · Radiotherapy, Intensity-Modulated (5) · toripalimab (4) · 130-nm albumin-bound paclitaxel (2) · Radiation (2) · spartalizumab (2) · CCDC6 protein, human (1) · Cetuximab (1) · Chemoradiotherapy (1) · Chemotherapy, Adjuvant (1) · Docetaxel (1) · Endostatins (1) · Immune Checkpoint Inhibitors (1)
Sun Yat-sen University (22) · Chongqing University Cancer Hospital (2) · Hai-Qiang Mai,MD,PhD (2) · West China Hospital (2) · Cheng-En Hsieh (1) · Fudan University (1) · Guiquan Zhu (1) · Hummingbird Bioscience (1) · Hunan Cancer Hospital (1) · Jiangxi Provincial Cancer Hospital (1) · Lin Kong, MD (1) · National Cancer Institute (NCI) (1) · Qiaojuan Guo (1) · Sun Yat-Sen University Cancer Center (1) · The First Affiliated Hospital of Xiamen University (1)
China (34) · Taiwan (2) · Australia (1) · Hong Kong (1) · Indonesia (1) · Moldova (1) · Singapore (1) · South Korea (1)
Jun Ma, M.D. (3) · Allan Hildesheim, Ph.D. (1) · Budi Wiweko, MD (1) · Hai-Qiang Mai, MD,PhD (1) · Haiqiang Mai, MD,PhD (1) · Ming-Yuan Chen, MD, PhD (1) · Rodney Cheng En Hsieh, MD, PhD (1) · Victor Ho-Fun Lee, MD (1) · Xiaozhong Chen, MD (1)
PMID 19564532, PMID 22178121, PMID 29065104, PMID 31150573, PMID 31178151, PMID 31319091, PMID 34174189, PMID 34341578, PMID 34479871, PMID 35105519, PMID 35240053, PMID 35906199, PMID 36746459, PMID 37207654, PMID 38001101, PMID 38059788, PMID 38507662, PMID 38964333, PMID 39970442, PMID 40068595, PMID 40382318